BindingDB logo
myBDB logout

31 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
 41 Non-glycosidic/non-aminoalkyl-substituted indolocarbazoles as inhibitors of protein kinase CEBI TBA
16603355 44 Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.BDB Abbott Laboratories
17258463 27 Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt.BDB Abbott Laboratories
17523610 73 Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase b/akt inhibitors with reduced hypotension.BDB Abbott Laboratories
17451235 19 Rapid Evolution of 6-Phenylpurine Inhibitors of Protein Kinase B through Structure-Based Design.BDB Astex
17275837 4 A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera.BDB Astex
16249095 43 Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B.BDB UK Centre for Cancer Therapeutics
16678413 28 Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase.BDB Abbott Laboratories
16403626 55 Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.BDB Abbott Laboratories
16413780 64 Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.BDB Abbott Laboratories
16699172 59 Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity.BDB German Cancer Research Center
14998327 12 Structure-based optimization of novel azepane derivatives as PKB inhibitors.BDB Roche Diagnostics GmbH
15634010 10 Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants.BDB Max-Planck-Institut fuer Biochemie
15026054 55 Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum.BDB CNRS
11881998 32 First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease.BDB Instituto de Quimica Medica (CSIC)
15974571 62 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.BDB Johnson & Johnson Pharmaceutical
12747775 56 Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors.BDB Lilly Research Laboratories
12824014 284 Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.BDB Lilly Research Laboratories
14552792 53 Studies on cyclin-dependent kinase inhibitors: indolo-[2,3-a]pyrrolo[3,4-c]carbazoles versus bis-indolylmaleimides.BDB DCR&T, Lilly Spain S.A.
15149644 37 Synthesis of 1,7-annulated indoles and their applications in the studies of cyclin dependent kinase inhibitors.BDB Lilly Research Laboratories
15225699 27 Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors.BDB Lilly Research Laboratories
15771433 30 Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.BDB Johnson & Johnson Pharmaceutical
7518523 90 Identification of tricyclic analogs related to ellagic acid as potent/selective tyrosine protein kinase inhibitors.BDB Pfizer
12036372 143 Synthesis and protein kinase inhibitory activity of balanol analogues with modified benzophenone subunits.BDB Sphinx Laboratories
8978850 205 Synthesis and protein kinase C inhibitory activities of acyclic balanol analogs that are highly selective for protein kinase C over protein kinase A.BDB Sphinx Laboratories
1552513 36 Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity.BDB Roche Products Limited
 68 Novel Indolocarbazole protein kinase C inhibitors with improved biochemical and physicochemical properties.BDB Tumor Biology Center
8421286 44 Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction.BDB Roche Products Limited
1874734 53 The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C.BDB Laboratoires Glaxo
1732526 101 Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides.BDB Roche Products Limited